7th Circ. To Crawl Into Humira 'Patent Thicket' Dispute
By Bryan Koenig · February 23, 2021, 6:58 PM EST
The Seventh Circuit could dramatically affect the intellectual property landscape for biologic drugs after hearing oral arguments on Thursday from Humira buyers accusing AbbVie of wrongly employing a "patent thicket" to...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login